Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial (Trials, (2014), 15, 1, (160), 10.1186/1745-6215-15-160)

N.R. Hill, D. Lasserson, B. Thompson, R. Perera-Salazar, J. Wolstenholme, P. Bower, T. Blakeman, D. Fitzmaurice, P. Little, G. Feder, N. Qureshi, M. Taal, J. Townend, C. Ferro, R. McManus, F.D.R. Hobbs

Research output: Contribution to journalArticlepeer-review

Original languageUndefined
Publication statusPublished - 2022

Cite this